#South Korea #Seoul #Seegene #Springer Nature #Nature Awards

Seegene and Springer Nature Launch Nature Awards MDx Impact Grants for 2025-2026

Seegene Inc., a global leader in molecular diagnostics, has officially opened applications for the Nature Awards MDx Impact grants for the years 2025 to 2026, in collaboration with Springer Nature, a trusted name in scholarly publishing. This initiative is an exciting evolution in the effort to combat public health challenges, particularly focusing on antimicrobial resistance in urinary tract infections (UTI-DR).

The application period runs until November 20, 2025, with winners expected to be announced in August 2026. The grants aim to stimulate innovative research that can lead to significant advancements in the molecular diagnosis field. Selected researchers will have the opportunity to obtain funding up to $600,000, alongside exclusive access to Seegene’s PCR syndromic analysis tools, analytics, and software.

This grant initiative represents the third phase of the program that originally commenced in 2023, inviting researchers globally to propose product development ideas and clinical research projects that address unmet clinical needs. Up to 18 antibiotic resistance genes connected with urinary tract infections can be proposed as analytical targets, highlighting the importance of tailored studies and innovations in diagnostics.

Richard Hughes, Vice President of Publishing Services at Springer Nature, emphasized that this program aligns with their commitment to provide platforms that unite scientists and expand research initiatives. He underlined that the grants are designed to aid researchers in advancing diagnostic solutions that could change the landscape of healthcare worldwide.

Dr. Jik Young Park, Vice President and Head of Research and Development at Seegene, added that Seegene’s role is to equip scientists with the tools and technologies necessary for transforming innovative ideas into real-world applications. Working in conjunction with Springer Nature, Seegene seeks to facilitate global research collaborations by providing both funding and crucial access to PCR syndromic technologies. Through these efforts, they aim to speed up the development of molecular diagnostic methods that strive towards a vision of a world free from all diseases.

The Nature Awards MDx Impact grants are designed not only to supplement existing global diagnostic initiatives but also to grant researchers the resources needed to expedite practical solutions. Previous cycles, like those in 2024-2025, supported projects aimed at rapid identification methods for pathogens such as ViruResist Klebsiella pneumoniae and multiplex PCR analyses for detecting viruses in immunocompromised patients, illustrating the breadth and impact of these efforts.

About Seegene

Seegene, with over 20 years of expertise in the field, is at the forefront of molecular diagnostics. During the COVID-19 pandemic, the company delivered more than 340 million tests across over 100 countries, showcasing its significant global footprint in healthcare. Seegene's patented syndromic quantitative PCR technology allows for the simultaneous detection of up to 14 pathogens with similar symptoms within a single tube. This facilitates a broader scope of clinical significance by offering insights on both co-infection status and quantitative data, providing unique advantages in addressing complex infections.

As part of its Technology Exchange Initiative, Seegene incorporates its syndromic quantitative diagnostic technology alongside the Seegene Digitalized Development System (SGDDS) for cooperative diagnostic product development. This initiative aims to encourage global collaboration and move closer to their vision of a disease-free world.

For more information, visit Seegene.com and follow them on LinkedIn.

About Nature Portfolio

Nature Portfolio delivers high-quality products and services across various scientific disciplines, catering to the global research community. Founded in 1869, Nature is a premier international scientific journal, and Nature Portfolio also includes top-tier journals such as Nature Research, Nature Reviews, and open-access journals like Nature Communications, and Scientific Reports, thereby publishing crucial scientific discoveries worldwide.

Press Contact: [email protected]